Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer
暂无分享,去创建一个
E. Berns | C. Scott | K. Khanna | R. Pearson | G. McArthur | M. Wakefield | L. Mileshkin | R. Hannan | K. Hannan | Jian Kang | E. Sanij | O. Kondrashova | G. Poortinga | C. Cullinane | Purba Nag | K. Sheppard | Keefe T. Chan | Daniel Frank | Jinbae Son | J. Ahern | A. Trigos | Elizabeth Lieschke | J. Soong | Shunfei Yan | Jiachen Xuan | Sarah Ellis
[1] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.
[2] S. Fox,et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma , 2018, Nature Communications.
[3] Joseph V Bonventre,et al. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. , 2018, Cancer discovery.
[4] J. Bartek,et al. High speed of fork progression induces DNA replication stress and genomic instability , 2018, Nature.
[5] Y. Drew,et al. Emerging treatment options for ovarian cancer: focus on rucaparib , 2017, International journal of women's health.
[6] George Thomas,et al. Ribosome biogenesis in cancer: new players and therapeutic avenues , 2017, Nature Reviews Cancer.
[7] R. Rabadán,et al. Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers. , 2017, Molecular cell.
[8] Zachary C. Dobbin,et al. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer , 2017, Clinical Cancer Research.
[9] James X. Sun,et al. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2017, Cancer discovery.
[10] J. Zuber,et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. , 2017, Blood.
[11] Alan Ashworth,et al. PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.
[12] Jian Xian,et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours , 2017, Nature Communications.
[13] J. George,et al. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. , 2017, Cancer research.
[14] A. Ashworth,et al. PARP inhibitor combination therapy. , 2016, Critical reviews in oncology/hematology.
[15] S. Cantor,et al. Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells , 2016, Nature.
[16] K. Khanna,et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling , 2016, Oncotarget.
[17] S. Cantor,et al. Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.
[18] G. Shapiro,et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.
[19] Andrés Aguilera,et al. R loops: new modulators of genome dynamics and function , 2015, Nature Reviews Genetics.
[20] P. Brown,et al. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis , 2015, Oncotarget.
[21] B. McStay,et al. A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage , 2015, Genes & development.
[22] C. Scott,et al. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Jason Ellul,et al. A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes , 2015, Genome research.
[24] Stephen J. Elledge,et al. Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair , 2015, Nature.
[25] K. Peltonen,et al. Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress , 2014, Molecular Cancer Therapeutics.
[26] R. Hannan,et al. Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease , 2014, Cell & Bioscience.
[27] S. Fox,et al. Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts , 2014, Molecular oncology.
[28] Ralph R. Weichselbaum,et al. DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy , 2014, Science Translational Medicine.
[29] G. Mills,et al. Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair , 2014, Nature Communications.
[30] C. Bieberich,et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.
[31] D. Bowtell,et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.
[32] R. Hannan,et al. The nucleolus: an emerging target for cancer therapy. , 2013, Trends in molecular medicine.
[33] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[34] A. Ashworth,et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.
[35] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[36] Carleen Cullinane,et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.
[37] M. Hottiger,et al. Inheritance of silent rDNA chromatin is mediated by PARP1 via noncoding RNA. , 2012, Molecular cell.
[38] D. Cortez,et al. Analysis of protein dynamics at active, stalled, and collapsed replication forks. , 2011, Genes & development.
[39] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[40] H. Johnsen,et al. Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.
[41] R. Hannan,et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.
[42] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[43] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[44] Tom Moss,et al. UBF levels determine the number of active ribosomal RNA genes in mammals , 2008, The Journal of cell biology.
[45] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[46] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[47] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] Gordon K. Smyth,et al. Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..
[49] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[50] R. Pearson,et al. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. , 2016, Cancer discovery.